Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 14/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759921 | 0.92 | KDM4E (0.38) | SCN9AKDM4EHTTKMT2ASCN10A | |
| SCHEMBL22910813 | 0.84 | PDK2 (0.36) | HPGDENPP2ATXN2PDK2 | |
| SCHEMBL22910815 | 0.83 | NR1H4 (0.32) | SCN9ASCN10AENPP2ATXN2 | |
| SCHEMBL22910814 | 0.81 | P2RY12 (0.39) | HPGDPDK2 | |
| SCHEMBL16759842 | 0.81 | P2RY12 (0.39) | HPGDPDK2 | |
| SCHEMBL16759901 | 0.80 | SCN9A (0.34) | SCN9AKMT2ASCN10AATXN2 | |
| SCHEMBL22910817 | 0.80 | SCN9A (0.34) | SCN9AKMT2ASCN10AATXN2 | |
| SCHEMBL16759959 | 0.79 | SCN9A (0.37) | SCN9AHTTKMT2ASCN10ANAMPT | |
| SCHEMBL22911021 | 0.78 | PDK2 (0.36) | PDK2 | |
| SCHEMBL22911087 | 0.77 | ENPP2 (0.36) | KMT2ANAMPTENPP2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | SCN9A 4020/4885KDM4E 1515/4885HTT 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.